Diagnosis & Differentiation
Sarcomatoid mesothelioma vs. myogenic sarcoma: a strong case for diagnostic electron microscopy: a case report
Ultrastructural Pathology 2025 May 25 [Link] Nadine H Oury, Katherine Killian D O, Tim D Oury Abstract Mesothelioma is often considered a difficult diagnosis due to its rarity, the wide variety of histological patterns and the propensity of metastasis from cancers of unknown origin to serosal surfaces. The advent of numerous new immunochemical markers has…
Read MoreA four-miRNA signature as a potential biomarker of malignant mesothelioma patients from hand-spinning asbestos exposed area in Eastern China
Ecotoxicology and Environmental Safety 2025 July 1 [Link] Lijin Zhu, Shibo Ying, Xin Su, Wenke Yu, Kaili Yan, Wei Shen, Shuaiyue Hu, Zhaoqiang Jiang, Hailing Xia, Lingfang Feng, Yan Zeng, Junqiang Chen, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive malignant tumor of mesothelial origin that develops mainly in the parietal pleura…
Read MoreFrom asbestos exposure to carcinogenesis: Transcriptomic signatures in malignant pleural mesothelioma
Experimental and Molecular Pathology 2025 May 20 [Link] Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angela Rina, Francesca Mari, Maria Palmieri, Antonio Giordano, Elisa Frullanti Abstract Background: The incidence of malignant pleural mesothelioma (MPM) has surged due to widespread asbestos exposure, particularly since the mid-20th century. Despite significant advancements in cancer treatment,…
Read MoreDiagnostic value of cyclin D1 immunohistochemistry in differentiating malignant mesothelioma from reactive mesothelial proliferation
Annals of Diagnostic Pathology 2025 October [Link] Döndü Nergiz, Arsenal Sezgin Alikanoğlu, Dinç Süren Abstract Introduction: Although morphologic assessment carries utmost importance in differentiating malignant mesotheliomas (MM) from reactive mesothelial proliferations (RMP), sometimes it may fail to clearly differentiate between these two entities. The aim of this study is to evaluate the potential role of…
Read MoreBreaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…
Read MoreEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MoreSignificance of 18F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal mesothelioma
Nuclear Medicine Communications 2025 May 6 [Link] Hui Zhang, Lifang Pang, Jun Hou, Beilei Li, Yiqiu Zhang Abstract Objective: This study was aimed at evaluating the significance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) in the staging and differentiation of malignant peritoneal mesothelioma (MPeM). Materials and methods: We retrospectively analyzed clinical and imaging data of 21…
Read MoreThe Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…
Read MoreCytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway
Thoracic Cancer 2025 April [Link] Susumu Kirimura, Morito Kurata, Hironori Ishibashi, Yusuke Taniguchi, Yuko Kinowaki, Keisuke Sugita, Kenichi Okubo Abstract Introduction: Chemotherapy is crucial for treating pleural mesothelioma; however, the outcomes are poor, necessitating an urgent need to study the mechanism of chemotherapy resistance in mesothelioma cells. Human antigen R (HuR), an RNA-binding protein and…
Read MoreUtility and limitations of Merlin immunohistochemistry for mesothelioma diagnosis in tissue sections and cell blocks
Annals of Diagnostic Pathology 2025 August [Link] Kazuki Nabeshima, Makoto Hamasaki, Tomomi Furukawa, Shinji Matsumoto, Katsumi Takizawa, Makiko Adachi, Yuko Goto Abstract Distinguishing pleural mesothelioma (PM) from reactive mesothelial proliferations (RMP) can be challenging. In such cases, immunohistochemistry (IHC)-detected BAP1 or MTAP loss and FISH-detected CDKN2A homozygous deletion are effective. Merlin is the protein product…
Read More